Myositis is a disease characterized by inflammation of the muscles and is often associated with severe muscle weakness. The most common forms of myositis are polymyositis and dermatomyositis.
The presence of myositis-specific autoantibodies in patients can often be indicative of disease. National Jewish Health Advanced Diagnostic Laboratories offers a Myositis Panel, which assays for myositis-specific and myositis-associated autoantibodies to 16 antigens, including several anti-tRNA synthetase autoantibodies. The panel may be used as an important part of the evaluation in those patients with myositis or select cases of idiopathic interstitial pneumonia. The 16 autoantibody specificities detected with the panel are associated with a range of inflammatory muscle diseases.
About Our Myositis Panel
The National Jewish Health Advanced Diagnostic Laboratories Myositis Panel provides a semi quantitative in vitro assay for human IgG antibodies specific for 16 different antigens.
Five new antigens (highlighted in blue) have recently been added to the panel.
- Mi-2 alpha and beta: isoforms of the recombinant Mi-2 protein (nuclear helicase)
- Ku: recombinant protein
- PM-Scl75: recombinant 75kDa PM-Scl protein
- PM-Scl100: recombinant 100kDa PM-Scl protein
- Jo-1: native Jo-1 antigen (histidyl-tRNA synthetase), purified from calf and rabbit thymus
- SRP: recombinant protein (54kDa, signal recognition particle)
- PL-7: recombinant protein (threonyl-tRNA synthetase)
- PL-12: recombinant protein (alanyl-tRNA synthetase)
- EJ: recombinant protein (glycyl-tRNA synthetase)
- OJ: recombinant protein (isoleucyl-tRNA synthetase)
- MDA5: purified protein (melanoma differentiation-associated gene 5)
- NXP2: recombinant protein (nuclear matrix protein 2)
- TIF1 gamma: recombinant protein (transcription intermediary factor 1 gamma)
- SAE1: recombinant protein (small ubiquitin-like modifier-1 (SUMO-1) activating enzyme)